The original version of the paper [1] reports that “This ACTIVE I study was supported by Pfizer” (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. Therefore, we would like to correct the wording to read: “This ACTIVE I study was supported by Bristol-Myers Squibb and Sanofi-Aventis”. The authors apologize for any inconvenience this may have caused to the readers of this journal.
Reference
- Kikuchi, K.; Tancharoen, S.; Ito, T.; Morimoto-Yamashita, Y.; Miura, N.; Kawahara, K.-I.; Maruyama, I.; Murai, Y.; Tanaka, E. Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci 2013, 14, 18899–18924. [Google Scholar]
© 2014 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).